REVIEW ARTICLE

UPI JOURNAL OF CHEMICAL AND LIFE SCIENCES (UPI-JCLS)

ISSN: 2581-4648 (An International online Peer Reviewed Open Access Journal)

www.uniquepubinternational.com Published by Unique Pub International (UPI)

PHARMACEUTICAL COCRYSTALS

K. VINOD KUMAR[1], K.VYSHNAVI[2], N.REETHI[2], H.SIDDARDHA[2], A.VAIKUNTESWAR[2]

[1]*Professor, Department of Pharmaceutics, St.Ann's College of Pharmacy, Chirala*
[2]*Department of Pharmaceutics, St.Ann's College of Pharmacy, Chirala*

***Corresponding Author**
Dr. K. Vinod Kumar

DOI: https://doi.org/10.37022/jcls.v9i1.174

Received: 24 Nov 2025 Revised: 14 Jan 2026 Accepted: 09 Feb 2026

Abstract

Low aqueous solubility and concomitant oral bioavailability are the major glitches found in converting the active pharmaceutical ingredients to new pharmaceutical products. Many methods are in existence to improve the solubility of poorly water-soluble drugs. Co-crystallization is one of the unique techniques that aggregate two or more different chemical entities in a crystalline lattice via non-covalent bonding. Co-crystals are multi-component system of an active pharmaceutical ingredient and a conformer.

Keywords: *Solubility Enhancement, Pharmaceutical Cocrystals, Nano Cocrystals, Coformers, Crystallization Techniques, Oral Bioavailability.*

INTRODUCTION

Pharmaceutical cocrystals are crystalline materials composed of an active pharmaceutical ingredient (API) and one or more neutral coformers (such as acids, bases, or amides) in a definite stoichiometric ratio, held together by non-covalent interactions (mainly hydrogen bonding, π–π stacking, and van der Waals forces).

What Makes Cocrystals Important?

Many APIs suffer from poor aqueous solubility, dissolution rate, bioavailability, stability, or processability. Traditional approaches like salt formation are not always feasible (e.g., for non-ionizable drugs). Cocrystals offer a versatile alternative.The solid-state properties of active pharmaceutical ingredients (APIs) play a critical role in determining the quality, safety, and efficacy of drug products In recent years, increasing regulatory clarity has further accelerated the industrial adoption of pharmaceutical cocrystals. Regulatory agencies such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) now recognize cocrystals as distinct solid forms, comparable to salts and polymorphs. This recognition has encouraged pharmaceutical companies to integrate cocrystal technology into product development pipelines, not only to improve therapeutic performance but also as a strategic tool for life-cycle management and intellectual property enhancement [1].

Models, Theories, Principles and Advanced Strategies of Pharmaceutical Cocrystals

Supramolecular Synthon Model

The supramolecular synthon model is a cornerstone in the rational design of pharmaceutical cocrystals. A supramolecular synthon is defined as a structural unit within a crystal that arises from specific and predictable intermolecular interactions. In pharmaceutical systems, hydrogen bonding synthons are the most dominant due to their strength and directionality. This model enables the identification of reliable functional group interactions between an API and a co-former, thus facilitating targeted cocrystal formation.



Fig 01: Cocrystal types

Molecular Complementarity Model [2]

The molecular complementarity model focuses on the spatial and chemical compatibility between the API and the co-former. Successful cocrystal formation requires complementary molecular size, shape, polarity, and functional group orientation. This complementarity ensures efficient molecular packing and maximizes intermolecular interactions within the crystal lattice.

Thermodynamic Model

The thermodynamic model explains cocrystal formation based on energy considerations. The process is governed by the Gibbs free energy change (ΔG), which must be negative for spontaneous cocrystal formation. The balance between enthalpic gains from strong intermolecular interactions and entropic losses due to ordered crystal formation determines overall stability.

Solubility-Based Model

The solubility-based model is widely used to explain the enhanced dissolution behavior of pharmaceutical cocrystals. According to this model, cocrystals exhibit altered solubility profiles due to changes in lattice energy and intermolecular interactions.

THEORIES OF PHARMACEUTICAL COCRYSTALS [3]

Hydrogen Bonding Theory

Hydrogen bonding theory is fundamental to the understanding of pharmaceutical cocrystals. Hydrogen bonds provide the primary cohesive force that stabilizes the multicomponent crystal lattice. The strength, directionality, and multiplicity of hydrogen bonds determine crystal packing and physical stability.

Acid–Base (ΔpKa) Theory

The ΔpKa theory offers a practical guideline for differentiating salt formation from cocrystallization. It is based on the proton transfer potential between the API and co-former. When the ΔpKa is less than zero, proton transfer is unlikely, favoring cocrystal formation through hydrogen bonding rather than ionic interactions.

Crystal Engineering Theory

Crystal engineering theory applies systematic design principles to manipulate crystal structures and properties. It integrates supramolecular chemistry, solid-state physics, and materials science. By controlling intermolecular interactions and crystal packing motifs, this theory enables the development of cocrystals with desired solubility, stability, and mechanical characteristics.

Lattice Energy Theory

Lattice energy theory explains the improved dissolution behavior of cocrystals by correlating lattice energy with solubility. High lattice energy crystals resist dissolution, whereas lower lattice energy systems dissolve more readily.
theory is particularly useful in explaining why certain cocrystals outperform amorphous forms in stability and bioavailability.

Principles of Pharmaceutical Cocrystals

Principle of Non-Covalent Pharmaceutical cocrystals are stabilized exclusively by non-covalent interactions, preserving the chemical integrity of the API. These interactions include hydrogen bonds, π–π interactions, and van der Waals forces, which collectively determine crystal stability and performance.

Stoichiometric and Structural Integrity Principle

Cocrystals exist in fixed stoichiometric ratios that ensure uniformity and reproducibility. Any deviation in stoichiometry can lead to phase separation or polymorphic transitions, affecting drug performance.

Solid-State Stability Principle

Solid-state stability is essential for the successful development of pharmaceutical cocrystals. Stability studies assess the resistance of cocrystals to moisture uptake, thermal stress, and mechanical forces during manufacturing and storage.

Regulatory and Safety Principle

From a regulatory perspective, cocrystals are treated as distinct solid forms. Co-formers must be non-toxic, pharmaceutically acceptable, and preferably included in GRAS lists. Regulatory agencies emphasize Principle of

Performance Enhancement

The ultimate goal of pharmaceutical cocrystals is to enhance drug performance. This includes improved solubility, dissolution rate, bioavailability, stability, and manufacturability, thereby supporting patient compliance and therapeutic efficacy.

Advanced Strategies of Pharmaceutical Cocrystal

Rational Crystal Engineering Strategy

This strategy involves systematic selection of co-formers based on functional group compatibility and intermolecular interaction patterns. It reduces experimental uncertainty and improves development efficiency.

High-Throughput and Automated Screening

High-throughput techniques allow rapid identification of suitable cocrystal systems by screening multiple co-formers and preparation methods simultaneously. This approach significantly shortens development timelines.

Computational and In-Silico Approaches

In-silico tools predict cocrystal formation, stability, and physicochemical properties. These methods reduce experimental cost and guide rational decision-making during formulation development.

Green and Sustainable Cocrystallization

Sustainable strategies focus on minimizing solvent use and environmental impact. Mechanochemical methods are gaining attention due to their scalability and eco-friendly nature.

Multi-Component and Nano-Cocrystal Strategies

Multi-component cocrystals enable simultaneous modification of multiple properties, while nano-cocrystals enhance dissolution and bioavailability through particle size reduction and increased surface area.

Application of pharmaceutical coccrystals

Cocrystal formation results in a new crystal structure, which is entirely independent from any of the starting materials. This new crystal structure imparts a new set of physical properties, also independent of and indifferent to the physical properties of any of the starting materials. Currently, the crystal structure and resulting physical properties of a cocrystal cannot be predicted from any property of the starting materials. As a result of potential physical property improvements, cocrystal applications are many and continue to grow.

Solubility

The expected impact of the coformer on cocrystal solubility is lacking in the majority of published accounts. An extensive study by Pastore et al. addressed this exact issue in 2015 by comparing the solubility, dissolution, and permeability characteristics of raw carbamazepine with three of its cocrystals (vanillin, succinc acid, and nitropyridine N-oxide).

Bioavailability

Cocrystals bear the potential to enhance the delivery and clinical performance of drug products by modulating drug solubility, pharmacokinetics, and bioavailability. Stanton et al. have compared the improvement on the solubility and pharmacokinetics of AMG 517, a potent and selective transient receptor potential vanilliod 1 (TRPV1) antagonist, when cocrystallizing this drug with carboxylic acid (cinnamic acid and benzoic acid and amide conformers.

Multidrug Cocrystals

Combining multiple active pharmaceutical ingredients (APIs), into one unit dose has become a popular trend in the drug formulation industry.

Mechanical Properties Enhancement

Tableting is the most popular pharmaceutical dosage form due to its numerous technical and economic advantages. Low manufacturing cost; high production throughput; and ease of consumption, storage, and handling are some of these benefits. However, several deficiencies caused by poor flowability and mechanical properties have always been a difficulty along the way to successful tablet production [4].

Fig 02: Cocrystal Properties

ADVANTAGES OF PHARMACEUTICAL COCRYSTALS

- Drug property tuning without changing the API structure
- The active pharmaceutical ingredient (API) remains chemically unchanged, reducing regulatory and safety concerns.
- Improved patient compliance through smaller tablet size
- Enhanced solubility and bioavailability can reduce dose size, making tablets easier to swallow.
- Reduction of dose dumping risk
- Controlled dissolution behavior of cocrystals can minimize sudden drug release.
- Better performance in low-dose drugs
- Cocrystals are especially useful for potent drugs where uniform distribution is critical.
- Enhanced compatibility with excipients
- Cocrystals often interact more predictably with formulation excipients than amorphous forms [5].

CONCLUSION

Pharmaceutical cocrystals represent a powerful and versatile solid-state strategy for improving the physicochemical and biopharmaceutical performance of active pharmaceutical ingredients without altering their chemical structure. Guided by supramolecular design principles, thermodynamic considerations, and crystal engineering theories, cocrystals enable enhancement of solubility, dissolution rate, bioavailability, stability, and mechanical properties. Regulatory recognition has further strengthened their role in modern drug development and life-cycle management. Advanced approaches such as computational modeling, high-throughput screening, and nano-cocrystal technology continue to expand their potential. Overall, pharmaceutical cocrystals offer a scientifically robust and industrially feasible platform for next-generation drug formulation.

FUNDING

Nil

CONFLICT OF INTEREST

Not declared

ETHICAL STATEMNT AND INFORM CONSENT

Not Applicable

ACKNOWLEDGEMENT

Not Declared

REFERENCES

1. Tupe SA, Khandagale SP, Jadhav AB. Pharmaceutical cocrystals: an emerging approach to modulate physicochemical properties of active pharmaceutical ingredients. J Drug Deliv Ther. 2023;13(4):101–112. doi:10.22270/jddt.v13i4.6016
2. Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des. 2009;9(6):2950–2967. doi:10.1021/cg800795p
3. Guo M, Sun X, Chen J, Cai T. Pharmaceutical cocrystals: preparations, physicochemical properties and applications. Acta Pharm Sin B. 2021;11(8):2537–2564. doi:10.1016/j.apsb.2021.03.030
4. Cerreia Vioglio P, Chierotti MR, Gobetto R. Pharmaceutical aspects of salt and cocrystal forms of APIs and characterization challenges. Adv Drug Deliv Rev. 2017;117:86–110. doi:10.1016/j.addr.2017.05.009
5. Saha BK, Boro VR. Pharmaceutical cocrystals: a perspective. Cryst Growth Des. 2025;25(18):7353–7359. doi:10.1021/acs.cgd.5c00625